On June 6, Finnegan client Eli Lilly and Company filed suit in the District of New Jersey in a bid to keep India’s Hetero Drugs from producing a generic version of the blockbuster ADHD drug Strattera® for the U.S. market. The suit claims that Hetero's filing of the ANDA constituted an act of infringement and that “Lilly will be substantially and irreparably harmed by Hetero's infringing activities unless those activities are enjoined by this court.” Eli Lilly and Company is represented by Finnegan in this matter.
